Inspira Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

Rhea-AI Summary

Inspira (NASDAQ: IINN, IINNW) received a Nasdaq notice dated Feb 19, 2026, that it is not in compliance with Listing Rule 5550(b)(2) requiring a minimum market value of publicly held shares of $35,000,000.

The company has a 180-day cure period through Aug 18, 2026, to regain compliance by closing at or above $35,000,000 for 10 consecutive business days; trading of ordinary shares continues on Nasdaq.

Positive

• Shares remain listed and continue trading on Nasdaq
• 180-calendar-day cure period granted through Aug 18, 2026

Negative

• Minimum market value of publicly held shares is below $35,000,000
• Risk of Nasdaq delisting if compliance is not regained before Aug 18, 2026
• No assurance the company will be able to regain compliance

Key Figures

MVPHS requirement: $35,000,000 Compliance period: 180 calendar days Compliance deadline: August 18, 2026 +2 more

5 metrics

MVPHS requirement $35,000,000 Nasdaq Listing Rule 5550(b)(2) minimum market value of publicly held shares

Compliance period 180 calendar days Time allowed under Nasdaq Listing Rule 5810(c)(3)(C) to regain MVPHS compliance

Compliance deadline August 18, 2026 Date by which MVPHS must meet Nasdaq requirement

Required streak 10 consecutive business days Minimum duration MVPHS must be at or above $35,000,000 to regain compliance

Notice date February 19, 2026 Date of Nasdaq notification regarding MVPHS deficiency

Market Reality Check

Price: $0.5892 Vol: Volume 111,123 is low ver...

low vol

$0.5892 Last Close

Volume Volume 111,123 is low versus 20-day average of 1,462,338 (relative volume 0.08). low

Technical Price 0.5861 is trading below the 200-day MA of 0.99 and 64.48% under the 52-week high.

Peers on Argus

IINN was up 1.93% with mixed peer moves: MYO -7.29%, RBOT -6.51%, MODD -5.74% wh...

IINN was up 1.93% with mixed peer moves: MYO -7.29%, RBOT -6.51%, MODD -5.74% while ECOR +7.65% and NMTC +2.47%, pointing to a stock-specific setup.

Historical Context

5 past events · Latest: 2026-02-18 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2026-02-18	U.S. deployment	Positive	-2.5%	ART100 deployed for structured commercial evaluation at top New York center.
2026-02-17	Commercial strategy	Positive	+0.8%	ART100 to be showcased at AmSECT 2026 via U.S. distributor Glo-Med.
2026-02-12	Nasdaq bid notice	Negative	-3.9%	Nasdaq notification for non-compliance with $1.00 minimum bid price rule.
2026-02-09	Major HMO approval	Positive	-5.6%	Vendor approval enabling ART100 deployment across Clalit’s hospitals and clinics.
2026-02-05	Equity financing	Negative	-6.5%	Registered direct offering and concurrent private placement priced at-the-market.

Pattern Detected

Positive commercial and financing updates have often seen negative price reactions, while Nasdaq compliance notices have generally aligned with downside moves.

Recent Company History

Recent news for IINN combined commercial traction with regulatory and financing overhangs. Deployments and evaluations of the FDA-cleared ART100 in leading U.S. centers and vendor approval at a major HMO coincided with negative price reactions. A registered direct offering and private placement on Feb 5, 2026 also saw a decline. Earlier in February, a Nasdaq minimum bid price notification aligned with additional weakness. Today’s minimum market value deficiency notice continues this theme of listing-compliance pressure overlaying commercial progress.

Regulatory & Risk Context

Active S-3 Shelf · $75,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-25

$75,000,000 registered capacity

The company has an active Form F-3/A shelf filed on 2025-11-25, allowing offerings of up to $75,000,000 in ordinary shares, warrants and units from time to time; it has been used at least once via a 424B5 prospectus supplement on 2025-12-15.

Market Pulse Summary

This announcement adds a second Nasdaq compliance issue, now focused on the $35,000,000 market value...

Analysis

This announcement adds a second Nasdaq compliance issue, now focused on the $35,000,000 market value of publicly held shares requirement, alongside an earlier minimum bid price notice. With IINN trading below its 0.99 200-day MA and far under its 52-week high, the 180-day window to regain compliance before August 18, 2026 becomes a key milestone. Investors may watch for corporate actions, any use of the $75,000,000 shelf, and further Nasdaq correspondence as important signals.

Key Terms

market value of publicly held shares, nasdaq capital market, listing rule 5550(b)(2), compliance date, +1 more

5 terms

market value of publicly held shares financial

"requiring companies listed on the Nasdaq Capital Market to maintain a minimum market value of publicly held shares of $35,000,000"

The market value of publicly held shares is the total dollar worth of a company’s shares that are available to outside investors, calculated by multiplying the current market price by the number of shares held by the public (the “float”). It matters because it tells investors how much of the company is actually tradable and how the market is pricing that tradable portion—like a price tag on the items on a store shelf, it affects liquidity, volatility and how easy it is to buy or sell a meaningful stake.

nasdaq capital market regulatory

"requiring companies listed on the Nasdaq Capital Market to maintain a minimum market value"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

listing rule 5550(b)(2) regulatory

"it received written notice ... not in compliance with Listing Rule 5550(b)(2)"

A Nasdaq listing rule that sets the minimum share-price requirement for companies on the Nasdaq Capital Market and describes how firms can remain listed if their stock trades below that floor but they meet other financial or market-size tests. For investors, it matters because falling below the rule can trigger delisting risk—like a product failing a quality check—while meeting the alternative tests can buy time and affect liquidity, visibility and access to capital.

compliance date regulatory

"until August 18, 2026 (the “Compliance Date”), to regain compliance"

The compliance date is the specific day by which a company must meet a legal, regulatory, contractual or stock-exchange requirement. Think of it like a deadline to pass an inspection or satisfy a contract term: if the company meets the deadline, normal operations continue; if it misses it, investors may face fines, changed contract terms, delisting, or other financial consequences. Investors watch these dates because they can trigger material changes in risk, cash flow, or share liquidity.

nasdaq hearings panel regulatory

"the Company may appeal the delisting determination to a Nasdaq hearings panel"

A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

AI-generated analysis. Not financial advice.

Ra’anana, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira  Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that on February 19, 2026, it received written notice (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) advising the Company that it was not in compliance with Listing Rule 5550(b)(2) requiring companies listed on the Nasdaq Capital Market to maintain a minimum market value of publicly held shares of $35,000,000 (the “MVPHS Requirement”). Listing Rule 5550(b)(2) requires companies listed on the Nasdaq Capital Market to maintain a minimum market value of publicly held shares of $35,000,000. The Notice has no effect at this time on the listing of the Company's ordinary shares, which continues to trade on The Nasdaq Capital Market under the symbol “IINN.”

In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has a period of 180 calendar days, or until August 18, 2026 (the “Compliance Date”), to regain compliance with the MVPHS Requirement. To regain compliance, the Company's minimum market value of publicly held shares must close at $35,000,000 or more for a minimum of 10 consecutive business days prior to the Compliance Date. In the event the Company does not regain compliance with the MVPHS Requirement prior to the Compliance Date, Nasdaq will notify the Company that its securities are subject to delisting, at which point the Company may appeal the delisting determination to a Nasdaq hearings panel.

 The Company intends to actively monitor its minimum market value of listed securities and may, if appropriate, consider implementing available options to regain compliance with the MVPHS Requirement. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5550(b)(2) or maintain compliance with any other listing requirements.

About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.

Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses its ability to regain compliance with the MVPHS Requirement, its intentions to actively monitor its minimum market value of listed securities and its plans to consider implementing available options to regain compliance with the MVPHS Requirement. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC's website at www.sec.gov.

Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485

FAQ

What did Inspira (IINN) receive from Nasdaq on February 19, 2026?

The company received a written notice that it is not compliant with the $35,000,000 MVPHS requirement. According to the company, Nasdaq advised Inspira it has a 180-day cure period ending Aug 18, 2026 to regain compliance.

How long does Inspira (IINN) have to regain Nasdaq compliance?

Inspira has a 180-calendar-day cure period ending on Aug 18, 2026. According to the company, it must close at or above $35,000,000 for 10 consecutive business days before that date to regain compliance.

What happens if Inspira (IINN) does not regain compliance by Aug 18, 2026?

Nasdaq will notify the company that its securities are subject to delisting. According to the company, Inspira may then appeal the delisting determination to a Nasdaq hearings panel.

Does the Nasdaq notice affect trading of Inspira (IINN) ordinary shares now?

No — the notice has no immediate effect on listing and shares continue trading on Nasdaq. According to the company, ordinary shares remain listed and actively trade under the symbol IINN.

What steps might Inspira (IINN) consider to regain Nasdaq compliance?

The company said it will actively monitor market value and may consider available options to regain compliance. According to the company, potential actions could be implemented if deemed appropriate to meet the MVPHS requirement.